logo
logo
  • About us
    • Reig Jofre in brief
    • Strategic pillars
    • Company history
    • Locations
  • Products
    • Product categories
    • Pharmaceutical Technologies
      • Antibiotics
      • Injectable products
      • Others
    • Specialty Products
      • Skin, Hair & Nail Health
      • Joint Health & Pain
      • Women’s Health
      • Respiratory / ENT
      • Pediatrics
    • Consumer Healthcare
    • Healthcare professionals and consumers corner
  • R&D
    • R&D
    • Innovation in Collaboration
    • Pipeline
    • Joint projects
  • Services
    • CDMO services
    • CMO services
  • Investors
    • Information note
    • General information
    • Inside information
    • Other relevant information
    • Former relevant facts
    • Financial information
    • Corporate governance
    • General shareholders’ meetings
    • The share
    • Analysts covering the stock
    • Presentations
    • Webcasts
  • News
    • News and repository
    • Reig Jofre in the media (ES)
    • Subscription center
  • Social Responsibility
  • Contact
    • Contact form
    • Work with us
  • |
  • ES
  • EN

News

Transparency withour stakeholders

  • Show all
  • 2021
  • 2020
  • 2019
  • 2018
  • 2017
  • 2016
  • 2015
  • 2014
  • 2013
  • 2012
  • 2011

3 August 2018

Transactions within the share buyback program

3 August 2018

Start of the trading of the new shares following the scrip dividend

30 July 2018

Transactions within the share buyback program

26 July 2018

Reig Jofre releases first half 2018 results note

25 July 2018

Start of the third Temporary Share Buyback Program

17 July 2018

Scrip dividend: bonus-shares capital increase and new shares to be issued

21 June 2018

Start of coverage through three equity research reports

14 June 2018

Scrip dividend: beginning of the trading period of the allotment rights

7 June 2018

Remuneration through the scrip dividend or flexible dividend

8 May 2018

Results note: First quarter 2018

3 May 2018

Resolutions on the general shareholders’ meeting

9 April 2018

Investment plan to expand the injectable products plant of Barcelona

23 March 2018

Convening of the Ordinary and Extraordinary General Shareholders’ Meeting

23 March 2018

Reig Jofre and Leanbio create the joint venture Syna Therapeutics for the development of biosimilar products

2 March 2018

Presentation of 2017 results

28 February 2018

Results preview: Year 2017

20 February 2018

Reig Jofre informs on the presentation of 2017 results

26 January 2018

Publication schedule for 2018 results

24 January 2018

Launch in France of a new nutritional supplement of Forté Pharma

5 January 2018

Transactions within the share buyback program

  • 1
  • …
  • 4
  • 5
  • 6
  • 7
  • 8
  • …
  • 15

Legal advice – Online store access for employees – RJF connected

© 2020 Laboratorio Reig Jofre

This website uses cookies to improve your experience. We'll assume you're ok with this, but you can opt-out if you wish. Cookie settingsRead MoreAccept
Privacy & Cookies Policy

Privacy Overview

This website uses cookies to improve your experience while you navigate through the website. Out of these cookies, the cookies that are categorized as necessary are stored on your browser as they are essential for the working of basic functionalities of the website. We also use third-party cookies that help us analyze and understand how you use this website. These cookies will be stored in your browser only with your consent. You also have the option to opt-out of these cookies. But opting out of some of these cookies may have an effect on your browsing experience.
Necessary
Always Enabled

Necessary cookies are absolutely essential for the website to function properly. This category only includes cookies that ensures basic functionalities and security features of the website. These cookies do not store any personal information.

Non-necessary

Any cookies that may not be particularly necessary for the website to function and is used specifically to collect user personal data via analytics, ads, other embedded contents are termed as non-necessary cookies. It is mandatory to procure user consent prior to running these cookies on your website.

SAVE & ACCEPT

Privacy Preference Center

Privacy Preferences